Omeprazole before endoscopy in patients with gastrointestinal bleeding

Area of Science:

• Gastroenterology
• Clinical Pharmacology

Background:

• Maintaining a neutral gastric pH is crucial for clot stability over bleeding arteries.
• Upper gastrointestinal bleeding (UGIB) necessitates effective management strategies to prevent complications.

Purpose of the Study:

• To evaluate the efficacy of preemptive high-dose omeprazole infusion prior to endoscopy in reducing the need for endoscopic therapy in UGIB patients.

Main Methods:

• A randomized controlled trial involving 638 patients with UGIB.
• Patients received either intravenous omeprazole (80 mg bolus + 8 mg/hr infusion) or placebo before endoscopy.
• Outcomes assessed included the need for endoscopic treatment, recurrent bleeding, surgery, mortality, and hospital stay.

Main Results:

• The omeprazole group showed a significantly lower need for endoscopic treatment (19.1% vs. 28.4%, P=0.007).
• Omeprazole use was associated with fewer actively bleeding ulcers and more ulcers with clean bases on endoscopy (P=0.01 and P=0.001, respectively).
• Patients receiving omeprazole had shorter hospital stays (P=0.005), with no significant differences in blood transfusion, recurrent bleeding, emergency surgery, or 30-day mortality.

Conclusions:

• Preemptive high-dose omeprazole infusion before endoscopy accelerates the resolution of bleeding signs in ulcers.
• This strategy effectively reduces the requirement for endoscopic therapy in patients with upper gastrointestinal bleeding.
• The findings support the use of high-dose omeprazole as an adjunct in managing UGIB.